OR WAIT null SECS
Studying AstraZeneca Drug for Generalized Anxiety Disorder
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-Quintiles Transnational Corp. today announced the achievement of another industry-leading milestone-its 400th clinical trial using Electronic Data Capture (EDC).
In addition to starting its 400th EDC trial, Quintiles has locked databases-the final step in data capture-on more than 270 EDC trials since 2000. To date, Quintiles has enrolled more than 400,000 patients at about 30,000 sites around the world using EDC. The milestone study is a Phase II trial for AstraZeneca’s AZD7325 – a GABA receptor sub-type partial agonist being developed for the treatment of anxiety.
“We are delighted that AstraZeneca has chosen Quintiles to help in the development of its innovative anti-anxiety medicine,” said Paula Brown Stafford, Executive Vice President, Integrated Clinical Services, Quintiles. “As the industry continues to adopt EDC and other time-saving technologies and processes, more patients will benefit sooner from new, breakthrough therapies.”
Alex, O’Toole, Global Head of EDC for Quintiles, said: “Quintiles’ ability to scale up the use of EDC while maintaining great performance for our customers and our clinical investigators is unparalleled in the CRO marketplace. We know this from regular surveys of our users that allow us to track their experience as we increase the number of EDC trials. Our surveys also help us to confirm the right system choice. We find that the majority of our investigators prefer the systems we offer and that the functionality helps them do their jobs more effectively.”
The AstraZeneca trial is a multi-center, randomized, placebo-controlled, double-blind trial to study the safety and efficacy of AZD 7325 for generalized anxiety disorder. Quintiles will use EDC to improve quality and shorten the time needed for evaluation of data at the conclusion of the study.
Brad Bower, one of AstraZeneca’s Clinical Leaders within the Neuroscience area, said: “We selected Quintiles to support delivery of this study because of their extensive clinical research expertise, experience and global reach. We ourselves look to leverage the benefits of technology in the delivery of our studies including web-based data capture, so the fact that they have harnessed EDC for this trial helps to enhance the delivery and efficiency of the program.”
Quintiles Transnational Corp. helps bring new medicines to market and peak sales faster by providing innovative, high-quality development, partnerships and commercialization solutions to the pharmaceutical and biotechnology industries. With more than 22,000 employees and offices in more than 50 countries, Quintiles is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company’s Web site at
AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: